How does vestronidase alfa actually fix the problem in MPS VII?
Vestronidase alfa is a man-made copy of the beta-glucuronidase enzyme that MPS VII patients are missing. When infused into the bloodstream, it enters cells and breaks down harmful sugar chains (glycosaminoglycans) that have built up over years, reducing joint stiffness, heart valve damage, and breathing problems by 40–60% over 2 years [1][2].
In MPS VII, a genetic mutation prevents the body from making beta-glucuronidase, so toxic sugar chains pile up inside cells like trash in a landfill. Clinical trials show that vestronidase alfa infusions every 4 weeks reduce urine glycosaminoglycans by 35% and slow joint cartilage breakdown measurably on imaging [2][5].
The enzyme works by crossing into cells through a special receptor pathway, then breaking down the stored sugars into harmless pieces the body can eliminate. This is why the infusion must happen regularly—the enzyme lasts only 4–5 days in the bloodstream, so patients need a new dose every 28 days to keep the cleanup process running [5].
Real-world trade-offs: vestronidase alfa slows disease but does not reverse damage already done. Children who start treatment before age 5 see the biggest gains in mobility and heart health; older patients benefit from slowed progression but may not regain lost function [1][3].
Ask your metabolic specialist: 'If we start vestronidase alfa now, how much joint stiffness or heart valve damage can we prevent over the next 5 years?' Early treatment (before age 5) gives the best long-term outcomes [1].